Nivolumab, an FDA-approved IgG4 anti-PD-1 monoclonal antibody for NSCLC, is used after platinum-based chemotherapy for patients with high or low PD-L1 expression. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.